Company Overview
Rocket Pharmaceuticals, Inc. operates as a late-stage biotechnology entity dedicated to the development, manufacturing, and commercialization of genetic therapies designed to address rare and devastating diseases within the United States market. The company functions within the broader Healthcare sector, specifically specializing in the Biotechnology industry, which focuses on the application of scientific research to create new biological treatments for medical conditions. According to the available data, the firm employs a workforce of 202 individuals to support its extensive research and development pipeline centered on in vivo adeno-associated viral (AAV) programs. With a market capitalization of $508.10M and annual revenue figures listed as not available, the company's valuation reflects the high-risk, high-reward nature typical of biotechnology firms in early to late-stage development. The absence of reported revenue in the traditional sense indicates that the company is likely focused on product development rather than widespread commercial sales, a common characteristic for late-stage biotech entities that have not yet achieved full market penetration for their primary therapies.
Financial Health
The financial statements for Rocket Pharmaceuticals, Inc. report a net income of $-223,123,000 and an EBITDA of $-217,491,000, while revenue is recorded as not available. The significant gap between the reported revenue metric and the substantial net loss reveals a cost structure dominated by research and development expenses that exceed current revenue generation. Free cash flow stands at $-104,854,376, indicating that the company is burning through its capital reserves to fund its operational activities and pipeline advancement. Despite these cash outflows, the balance sheet maintains $188.93M in cash against $24.88M in debt, suggesting a robust liquidity position relative to its obligations. However, the gross margin, operating margin, and profit margin are all recorded at 0.0%, which indicates that the company has not yet generated sufficient gross profit to cover operating expenses or arrive at a net profit on a per-unit basis. The debt-to-equity ratio of 8.97 suggests a highly leveraged capital structure, yet the current ratio of 6.38 demonstrates strong short-term liquidity, meaning the company possesses ample current assets to cover its short-term liabilities. Return on Equity is -60.3% and Return on Assets is -33.3%, metrics that mathematically reflect the dilutive impact of losses on shareholder equity and asset base, highlighting that management is currently deploying capital to create future value rather than generating immediate returns.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as not available, while the forward P/E is recorded as -3.86, implying that the market is pricing in future earnings expectations that are currently negative but potentially turning positive. The price-to-book ratio stands at 1.83, indicating that the market values the company at a premium of 83% above its book value, a metric often seen in biotech firms where intellectual property and pipeline potential are valued higher than tangible assets. The price-to-sales ratio is not available, and the EV/EBITDA is -1.58, suggesting that traditional multiple-based valuation models are less applicable due to the lack of profitability and the specific nature of the company's asset base. Over the last year, the stock has traded between a 52-week low of $2.19 and a 52-week high of $8.80, meaning the current valuation fluctuates significantly within a range that reflects high investor sentiment volatility. The beta of 0.45 indicates that the stock's price volatility is significantly lower than the broader market, suggesting that RCKT moves less dramatically than the S&P 500 despite its high-risk operational profile.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as not available, which precludes a direct comparison of earnings growth rates against revenue growth rates in the traditional sense. Since the company does not pay a dividend, there is no dividend yield or payout ratio to evaluate for sustainability; instead, the firm reinvests all available earnings and cash reserves back into its genetic therapy development programs. The absence of dividend payments is consistent with the company's life-stage strategy, where capital is prioritized for pipeline expansion rather than distribution to shareholders. Overall, the growth and income profile is defined by a lack of current earnings growth data and a complete reliance on internal capital generation and external financing to sustain operations and advance the in vivo adeno-associated viral (AAV) programs.